About The Study
Cytomegalovirus (CMV) is a common and widespread virus that is often overlooked because healthy people who contract is often show no signs or symptoms. But if a woman becomes infected with CMV while she is pregnant, she can pass the infection to her unborn baby. This can cause her child to suffer long-term disability due to birth defects, including hearing loss, or even death in very severe cases.
Currently, there is no approved vaccine against this devastating virus. That is why it is so important that we work together to make sure investigational vaccines are safe and effective to protect the most vulnerable against infection.
Researchers are conducting a clinical trial to evaluate the efficacy and safety of an investigational vaccine called mRNA-1647 against CMV infection in healthy female adults ages 16 to 40.
Study Criteria
To qualify, participants must:
- Be a female between 16-40 years of age
- Be in good health
- Be in close contact, or anticipate having contact, with at least one child 5 years of age or younger for at least 8 hours a week, if age 20 or older
- Not be pregnant or planning on becoming pregnant within the next 10 months
Why Participate?
There is no cost to participate and health insurance is not required to participate. Participants will receive all study-related visits and investigational vaccine or placebo at no cost. Eligible participants will receive compensation up to $2,078.00 total for completing the study based upon the number of visits completed.
